The Adrenocortical Carcinoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Adrenocortical Carcinoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Adrenocortical Carcinoma pipeline landscape and fostering the potential growth of Adrenocortical Carcinoma therapeutic advancements.

 

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report

• DelveInsight’s Adrenocortical Carcinoma pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
• The leading companies working in the Adrenocortical Carcinoma market include Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others.
• Promising Adrenocortical Carcinoma Pipeline Therapies in the various stages of development include Relacorilant, Pembrolizumab, OSI-906, 68Ga-R8760 Injection, ATR-101, Nivolumab, Sunitinib, TKM-080301, Axitinib, Iressa (ZD1839), and others.
• On March 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase 2 clinical trials for Pembrolizumab. Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
• On August 2023, Corcept Therapeutics announced a study of Phase 1 clinical trials for Relacorilant and Pembrolizumab. This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
• On August 2023, Radionetics Oncology announced a study of Phase 1 clinical trials for 68Ga-R8760 injection. A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers.
• On August 2023, Enterome announced a study of Phase 1 & 2 clinical trials foer EO2401 and Nivolumab. This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

 

Request a sample and discover the recent advances in Adrenocortical Carcinoma Treatment Drugs @ Adrenocortical Carcinoma Infection Pipeline Report

 

The Adrenocortical Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Adrenocortical Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Adrenocortical Carcinoma clinical trial landscape.

 

Adrenocortical Carcinoma Overview

Adrenocortical carcinoma is a cancer that forms in the outer layer (cortex) of the adrenal glands. There are two adrenal glands, one located at the top of each kidney. The adrenal cortex makes hormones — including cortisol, testosterone, aldosterone and estrogen.

 

Find out more about Adrenocortical Carcinoma Treatment Drugs @ Drugs for Adrenocortical Carcinoma Treatment

 

Adrenocortical Carcinoma Emerging Drugs Profile

• Relacorilant: Corcept Therapeutics
• Ipilimumab: Bristol-Myers Squibb

 

Adrenocortical Carcinoma Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Adrenocortical Carcinoma. The Adrenocortical Carcinoma companies which have their Adrenocortical Carcinoma drug candidates in the most advanced stage, i.e. pre-registration include, CRISPR Therapeutics.

 

Learn more about the emerging Adrenocortical Carcinoma Pipeline Therapies @ Adrenocortical Carcinoma Clinical Trials Assessment

 

Scope of the Adrenocortical Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech, and others.
• Adrenocortical Carcinoma Pipeline Therapies- Relacorilant, Pembrolizumab, OSI-906, 68Ga-R8760 Injection, ATR-101, Nivolumab, Sunitinib, TKM-080301, Axitinib, Iressa (ZD1839), and others.

 

Dive deep into rich insights for new drugs for Adrenocortical Carcinoma treatment, Visit @ Adrenocortical Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Adrenocortical Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adrenocortical Carcinoma– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Ipilimumab: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. Relacorilant: Corcept Therapeutics
12. Preclinical and Discovery Stage Products
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Adrenocortical Carcinoma Key Companies
17. Adrenocortical Carcinoma Key Products
18. Adrenocortical Carcinoma- Unmet Needs
19. Adrenocortical Carcinoma- Market Drivers and Barriers
20. Adrenocortical Carcinoma- Future Perspectives and Conclusion
21. Adrenocortical Carcinoma Analyst Views
22. Adrenocortical Carcinoma Key Companies
23. Appendix

 

For further information on the Adrenocortical Carcinoma pipeline therapeutics, reach out to Adrenocortical Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services